12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Votrient pazopanib regulatory update

In July, GlaxoSmithKline submitted an sNDA to FDA and a Type II variation to EMA for Votrient pazopanib to treat advanced soft tissue sarcoma patients...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >